SynthesisFrontiers in endocrinology2025
Dapagliflozin improves cardiac function and reduces adverse events in myocardial infarction: a meta-analysis in diabetic and non-diabetic populations.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Dapagliflozin Protects Cardiomyocytes against Doxorubicin-Induced Toxicity by Modulating Sirtuin 1/Sirtuin 3 and Ferroptosis Pathway.ACS pharmacology & translational science · 2026Article
- Sweet relief: exploring mechanisms and therapeutic approaches of sodium-glucose cotransporter-2 inhibitors in cardiovascular-kidney metabolic syndrome.Cardiovascular diabetology · 2026Review
- Analysis of the effects of dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in heart failure patients with preserved ejection fraction after percutaneous coronary intervention.European journal of translational myology · 2026Article
- Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI-Treated Acute Myocardial Infarction: A Meta-Analysis of Clinical Efficacy and Safety.Cardiology research and practice · 2026Review
- Sodium-Glucose Cotransporter-2 Inhibitors Following Acute Myocardial Infarction in Patients Without Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.Clinical Medicine Insights. Cardiology · 2026Article
- Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI).Journal of the Saudi Heart Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, frequently driven by acute coronary occlusion resulting from atherosclerosis and arrhythmias. Type 2 diabetes mellitus (T2DM) is a major risk factor for atherosclerotic progression and is associated with worsened cardiovascular outcomes in post-MI patients. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged as a novel antidiabetic agent with additional cardiovascular benefits. Increasing evidence suggests its potential utility in post-MI care, particularly in patients with coexisting T2DM. Objective: This study aims to systematically evaluate the clinical efficacy of dapagliflozin in improving cardiac function and reducing adverse cardiovascular events in post- MI patients with and without diabetes. Methods: A systematic search of PubMed, Embase, Web of Science, Cochrane Library, CNKI, and WanFang databases identified relevant clinical studies up to May 22, 2024. Eligible randomized controlled trials (RCTs) and retrospective cohort studies were analyzed using Review Manager 5.3. Results: 19 studies (12 RCTs and 7 cohort studies) with 7,128 patients were included. Meta-analysis showed dapagliflozin significantly reduced key cardiac biomarkers and structural parameters, including NT-proBNP (MD = -62.06, 95% CI [-94.59, -29.53], P = 0.0002), LVEDD (MD = -2.58, 95% CI [-3.64, -1.52], P < 0.00001), and LVESD (MD = -2.32, 95% CI [-2.99, -1.66], P < 0.00001), while enhancing LVEF (MD = 3.88, 95% CI [2.24, 5.52], P < 0.00001). It also reduced major adverse cardiovascular events (RR = 0.33, 95% CI [0.18, 0.60], P < 0.05), and heart failure-related rehospitalization (RR = 0.53, 95% CI [0.30, 0.91], P < 0.05). Subgroup analysis revealed consistent cardioprotective benefits in both diabetic and non-diabetic populations. Conclusion: Dapagliflozin significantly enhances cardiac function and reduces adverse cardiovascular events in post-MI patients, independent of diabetes status. These findings support the integration of dapagliflozin into post-MI management strategies. Further large-scale, long-term clinical trials are needed to assess its impact on recurrent MI and long-term survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.